TrialLeukemia2021

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.

Meletios A Dimopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.